Gilead Sciences
Search results
We are one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. 13th Largest Pharma Company in India, In terms of Domestic Sales for MAT September 2023
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company, headquartered in Pune. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules) and injectables.
Sep 30, 2023 · Emcure Pharmaceuticals is driven by the purpose to develop, manufacture and market a broad range of pharmaceutical products globally. Our core strength and competitive advantage lie in our established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others.
1 day ago · Emcure Pharmaceuticals initial public offering is set to open for subscription on Wednesday, July, 3, 2024. The IPO comprises a fresh issue of 7.9 million shares totaling Rs 800.00 crores and an offer for sale of 11.4 million shares amounting to Rs 1,152.03 crores. The pharma company raised Rs 582 ...
3 days ago · Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
Emcure Pharmaceuticals is a fast-growing Indian pharmaceutical company engaged in developing, manufacturing & marketing a broad range of pharmaceutical products globally.
2 days ago · Emcure Pharmaceuticals, a Pune-based company, is involved in the development, production, and international marketing of a wide range of pharmaceutical products in several important therapeutic areas.
15 hours ago · The initial public offering (IPO) of Emcure Pharmaceuticals Limited has attracted attention from investors, with the public issue being fully subscribed.. The total subscription for Emcure Pharma IPO stands at 4.98 times as of 5 PM. Qualified Institutional Buyers (QIB) category was subscribed at 1.00 times, Non-Institutional Investors (NII) at 13.67 times, retail investors have a subscription of 3.43 times, employees at 4.83 times.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical company with a differentiated product portfolio. With its wide range of offerings, Emcure Pharmaceuticals has cemented its presence in over 70 countries around the world.
1 day ago · Emcure Pharma's initial public offering is a mix of fresh issuance of shares worth Rs 800 crore, and an offer-for-sale (OFS) of 1.14 crore shares worth Rs 1,152.03 crore.
